NeuroPace (NPCE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Apr, 2026Voting matters and shareholder proposals
Election of two Class II director nominees, Lisa Andrade and Scott Huennekens, to serve until the 2029 Annual Meeting and until successors are elected and qualified.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxies are authorized to vote on any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Two director nominees are up for election to the board, each for a term expiring at the 2029 Annual Meeting.
Audit committee and external auditor matters
Proposal to ratify PricewaterhouseCoopers LLP as the independent auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from NeuroPace
- FDA approval for IGE and AI-driven tools could significantly expand market reach and accelerate growth.NPCE
12th Annual Cantor Fitzgerald Global Healthcare Conference - FDA approval for IGE could unlock significant growth, with commercialization ramping up by 2027.NPCE
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue up 17% to $22.8M, margins improved, and guidance was raised.NPCE
Q2 2026 - FDA requests more data for RNS System IGE expansion but sees a collaborative path to approval.NPCE
FDA announcement - Targeting 20%+ CAGR through 2027 with new indications, AI tools, and expanded market access.NPCE
Investor Day 2025 - Director elections and auditor ratification passed with strong shareholder support.NPCE
AGM 2026 - Q1 2026 revenue up 20% to $22.1M; guidance raised, with strong RNS and AI momentum.NPCE
Q1 2026 - Strong 2025 growth and margin gains set the stage for transformational expansion in 2026.NPCE
Q4 2025 - Q3 revenue up 28% YoY to $21.1M, net loss narrows, and 2024 guidance raised on RNS growth.NPCE
Q3 2024